nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the response to targeted therapy in patients with FGFR2 fusions, indicating that these genetic alterations correlate with treatment response. The mention of the E384X variant as a negative regulator of EGFR suggests its potential relevance in therapeutic contexts, particularly in relation to treatment strategies targeting the EGFR pathway.
Oncogenic: The E384X variant is described as an SNV in ERRFI1, which is a negative regulator of EGFR, implying its role in tumor biology and potentially contributing to tumor development or progression. This suggests that the variant may have oncogenic implications, particularly in the context of cholangiocarcinoma.
